SUBSCRIBE
SUBSCRIBE

MAIA Biotechnology

IN THE PRESS
Drug Development
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
February 7, 2024
 · 
7 min read
BioMidwest
MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds
January 24, 2024
 · 
5 min read
Drug Development
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
January 17, 2024
 · 
7 min read
BioMidwest
MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024
January 5, 2024
 · 
4 min read
Drug Development
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
December 19, 2023
 · 
6 min read
Deals
MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
November 17, 2023
 · 
5 min read
BioMidwest
MAIA Biotechnology Announces $4 Million Registered Direct Offering
November 15, 2023
 · 
6 min read
FDA
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma
November 10, 2023
 · 
8 min read
BioMidwest
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
November 7, 2023
 · 
9 min read
BioMidwest
MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO
October 30, 2023
 · 
6 min read
Load More
JOBS